Air Premia Becomes Member of IATA, Marking Major Milestone Toward Global Expansion

• Recognized for International Safety and Operational Excellence; Strengthening Global Competitiveness Through Strategic Cooperation

SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Air Premia, Korea's premium hybrid airline, announced today that it has officially joined the International Air Transport Association (IATA) as a member—an achievement that follows closely on the heels of the company receiving the latest IOSA (IATA Operational Safety Audit) registration. This dual milestone positions Air Premia as a rising global player in the international aviation industry.

Achieving IATA membership immediately after obtaining registration under the ISM (IOSA Standards Manual) 16th Edition is an exceptional case in the aviation sector. The recognition affirms that Air Premia's safety and operational systems meet the most rigorous international standards.

The airline earned its IOSA registration in May 2025, just three years after launching international operations in 2022. The registration validates compliance with more than 900 globally recognized safety and operational requirements. On June 1, Air Premia was officially registered as a member of IATA, becoming the seventh South Korean airline to receive this distinction.

IATA is the leading global trade association for the air transport industry, representing approximately 350 airlines across 120 countries. membership signifies a carrier's alignment with the highest levels of safety, reliability, and operational capability.

With IATA membership now secured, Air Premia expects to further elevate its international credibility while expanding its global cooperation network. The airline is actively considering participation in a major international airline alliances and other global aviation platforms—an initiative expected to accelerate the enhancement of its services and global competitiveness.

"This marks a pivotal moment for Air Premia as we continue our journey toward becoming a globally recognized airline," said Yoo Myung-sub, CEO of Air Premia. "Our IATA membership reflects our ongoing commitment to the highest safety standards and differentiated service. We will continue to pursue membership in a global airline alliance and enhance the travel experience for our customers."

Specializing in premium service on medium- to long-haul routes, Air Premia seeks to deliver a new standard of air travel. With a foundation of international certifications and industry recognition, the airline is committed to continued growth as a global carrier.

SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Air Premia, Korea's premium hybrid airline, announced today that it has officially joined the International Air Transport Association (IATA) as a member—an achievement that follows closely on the heels of the company receiving the latest IOSA (IATA Operational Safety Audit) registration. This dual milestone positions Air Premia as a rising global player in the international aviation industry.

Achieving IATA membership immediately after obtaining registration under the ISM (IOSA Standards Manual) 16th Edition is an exceptional case in the aviation sector. The recognition affirms that Air Premia's safety and operational systems meet the most rigorous international standards.

The airline earned its IOSA registration in May 2025, just three years after launching international operations in 2022. The registration validates compliance with more than 900 globally recognized safety and operational requirements. On June 1, Air Premia was officially registered as a member of IATA, becoming the seventh South Korean airline to receive this distinction.

IATA is the leading global trade association for the air transport industry, representing approximately 350 airlines across 120 countries. membership signifies a carrier's alignment with the highest levels of safety, reliability, and operational capability.

With IATA membership now secured, Air Premia expects to further elevate its international credibility while expanding its global cooperation network. The airline is actively considering participation in a major international airline alliances and other global aviation platforms—an initiative expected to accelerate the enhancement of its services and global competitiveness.

"This marks a pivotal moment for Air Premia as we continue our journey toward becoming a globally recognized airline," said Yoo Myung-sub, CEO of Air Premia. "Our IATA membership reflects our ongoing commitment to the highest safety standards and differentiated service. We will continue to pursue membership in a global airline alliance and enhance the travel experience for our customers."

Specializing in premium service on medium- to long-haul routes, Air Premia seeks to deliver a new standard of air travel. With a foundation of international certifications and industry recognition, the airline is committed to continued growth as a global carrier.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Air Premia Becomes Member of IATA, Marking Major Milestone Toward Global Expansion

Air Premia Becomes Member of IATA, Marking Major Milestone Toward Global Expansion

T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors

Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer

Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.

"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."

Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.

 

 

To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.

Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.

"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."

About Alamar Biosciences, Inc. 
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com. 

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team